Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1179-1950
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update ; volume:78 ; number:1 ; day:29 ; month:11 ; year:2017 ; pages:19-37 ; date:1.2018
Drugs ; 78, Heft 1 (29.11.2017), 19-37, 1.2018

Classification
Medizin, Gesundheit

Creator
Nijhof, Inger S.
Contributor
Donk, Niels van de
Zweegman, Sonja
Lokhorst, Henk M.
SpringerLink (Online service)

DOI
10.1007/s40265-017-0841-y
URN
urn:nbn:de:101:1-2018061321200705384368
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:26 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Nijhof, Inger S.
  • Donk, Niels van de
  • Zweegman, Sonja
  • Lokhorst, Henk M.
  • SpringerLink (Online service)

Other Objects (12)

Management of Relapsed and Refractory Multiple Myeloma: Recent advances

Management of Relapsed and Refractory Multiple Myeloma: Recent advances

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Update on the management of relapsed/refractory chronic lymphocytic leukemia

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Related objects